LLL12

LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth[1].

Product Specifications

CAS Number

[1260247-42-4]

UNSPSC

12352005

Target

STAT

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lll12.html

Purity

99.45

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(C(C=CC=C1C(C2=C3C=CC=C2O)=O)=C1C3=O)(N)=O

Molecular Formula

C14H9NO5S

Molecular Weight

303.29

References & Citations

[1]Zhang R, et al. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells. Oncol Rep. 2020 Sep;44 (3) :1224-1232.|[2]Onimoe GI, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012 Jun;30 (3) :916-26.